Drug Profile

Research programme: CD47/SIRPalpha pathway modulators - Prothya BioSolutions/Byondis

Alternative Names: CD47 antigen/SIRPalpha protein modulators; CD47-SIRPα modulators

Latest Information Update: 28 Jul 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sanquin Blood Supply Foundation
Developer Byondis; Prothya BioSolutions
Class Antineoplastics; Immunotherapies; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants; SIRPA protein inhibitors; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

28 Jul 2021 No recent reports of development identified for research development in Cancer in Netherlands (Parenteral)
16 Apr 2020 Synthon Biopharmaceuticals is now called Byondis
31 Jul 2018 Forty Seven sub-licenses patent pertaining to 5F9 from Synthon Biopharmaceuticals

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com